BPI 23314
Alternative Names: BPI-23314Latest Information Update: 15 Jun 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 BPI 23314 is still in phase I trials for Acute myeloid leukemia in China
- 05 Apr 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Acute myeloid leukemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in China (PO)